Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.

Pei Z, Chen C, Chen J, Cruz-Chuh JD, Delarosa R, Deng Y, Fourie-O'Donohue A, Figueroa I, Guo J, Jin W, Khojasteh SC, Kozak KR, Latifi B, Lee J, Li G, Lin E, Liu L, Lu J, Martin S, Ng C, Nguyen T, Ohri R, Lewis Phillips G, Pillow TH, Rowntree RK, Stagg NJ, Stokoe D, Ulufatu S, Verma VA, Wai J, Wang J, Xu K, Xu Z, Yao H, Yu SF, Zhang D, Dragovich PS.

Mol Pharm. 2018 Sep 4;15(9):3979-3996. doi: 10.1021/acs.molpharmaceut.8b00431. Epub 2018 Aug 6.

PMID:
30040421
2.

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.

Dompe N, Klijn C, Watson SA, Leng K, Port J, Cuellar T, Watanabe C, Haley B, Neve R, Evangelista M, Stokoe D.

PLoS One. 2018 Jun 18;13(6):e0199264. doi: 10.1371/journal.pone.0199264. eCollection 2018.

3.

Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.

Crawford TD, Vartanian S, Côté A, Bellon S, Duplessis M, Flynn EM, Hewitt M, Huang HR, Kiefer JR, Murray J, Nasveschuk CG, Pardo E, Romero FA, Sandy P, Tang Y, Taylor AM, Tsui V, Wang J, Wang S, Zawadzke L, Albrecht BK, Magnuson SR, Cochran AG, Stokoe D.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3534-3541. doi: 10.1016/j.bmcl.2017.05.063. Epub 2017 Jun 3.

PMID:
28606761
4.

The relationship between malnutrition risk and clinical outcomes in a cohort of frail older hospital patients.

Slee A, Birch D, Stokoe D.

Clin Nutr ESPEN. 2016 Oct;15:57-62. doi: 10.1016/j.clnesp.2016.06.002. Epub 2016 Jun 23.

PMID:
28531785
5.

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K.

Cell. 2017 Feb 23;168(5):817-829.e15. doi: 10.1016/j.cell.2017.01.020. Epub 2017 Feb 16.

6.

Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.

Lee HJ, Cao Y, Pham V, Blackwood E, Wilson C, Evangelista M, Klijn C, Stokoe D, Settleman J.

Mol Cancer Ther. 2017 Apr;16(4):694-704. doi: 10.1158/1535-7163.MCT-16-0504. Epub 2017 Jan 30.

7.

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.

Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, Daemen A, Bakalarski CE, Holcomb T, Shames DS, Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R, Stokoe D.

Cell Rep. 2016 Sep 6;16(10):2605-2617. doi: 10.1016/j.celrep.2016.08.010. Epub 2016 Aug 25.

8.

Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.

McGrath JP, Williamson KE, Balasubramanian S, Odate S, Arora S, Hatton C, Edwards TM, O'Brien T, Magnuson S, Stokoe D, Daniels DL, Bryant BM, Trojer P.

Cancer Res. 2016 Apr 1;76(7):1975-88. doi: 10.1158/0008-5472.CAN-15-2333. Epub 2016 Feb 2.

9.

Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.

Vartanian S, Ma TP, Lee J, Haverty PM, Kirkpatrick DS, Yu K, Stokoe D.

Mol Cell Proteomics. 2016 Apr;15(4):1220-31. doi: 10.1074/mcp.M115.055509. Epub 2015 Dec 28.

10.

A comprehensive transcriptional portrait of human cancer cell lines.

Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, Mukhyala K, Selvaraj SK, Yu M, Zynda GJ, Brauer MJ, Wu TD, Gentleman RC, Manning G, Yauch RL, Bourgon R, Stokoe D, Modrusan Z, Neve RM, de Sauvage FJ, Settleman J, Seshagiri S, Zhang Z.

Nat Biotechnol. 2015 Mar;33(3):306-12. doi: 10.1038/nbt.3080. Epub 2014 Dec 8.

PMID:
25485619
11.
12.

A comparison of the malnutrition screening tools, MUST, MNA and bioelectrical impedance assessment in frail older hospital patients.

Slee A, Birch D, Stokoe D.

Clin Nutr. 2015 Apr;34(2):296-301. doi: 10.1016/j.clnu.2014.04.013. Epub 2014 May 2.

PMID:
24835154
13.

Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.

Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ, Neve RM.

Cancer Res. 2014 Jun 1;74(11):3114-26. doi: 10.1158/0008-5472.CAN-13-2683. Epub 2014 Apr 22.

14.

Selective inhibition of mutant Ras protein through covalent binding.

Rudolph J, Stokoe D.

Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3777-9. doi: 10.1002/anie.201400233. Epub 2014 Mar 3.

PMID:
24590864
15.

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM, Stokoe D.

Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.

PMID:
23496764
16.

Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.

Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T, Stokoe D.

J Biol Chem. 2013 Jan 25;288(4):2403-13. doi: 10.1074/jbc.M112.394130. Epub 2012 Nov 27.

17.

Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.

Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H, Lorenzo MN, Yuan W, Guillory J, Jackson M, Rondon J, Franke Y, Bowman KK, Sagolla M, Stinson J, Wu TD, Wu J, Stokoe D, Stern HM, Brandhuber BJ, Lin K, Skelton NJ, Seshagiri S.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19368-73. doi: 10.1073/pnas.1204384109. Epub 2012 Nov 7.

18.

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, Chan J, Holcomb T, Dijkgraaf P, Johnson S, Koeman J, Minna JD, Gazdar AF, Stern HM, Hoeflich KP, Wu TD, Settleman J, de Sauvage FJ, Gentleman RC, Neve RM, Stokoe D, Modrusan Z, Seshagiri S, Shames DS, Zhang Z.

Genome Res. 2012 Dec;22(12):2315-27. doi: 10.1101/gr.140988.112. Epub 2012 Oct 2.

19.

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5299-304. doi: 10.1073/pnas.1116510109. Epub 2012 Mar 19.

20.

DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, Nelson HH, Stokoe D, Wiemels JL, Chang SM, Prados MD, Tihan T, Vandenberg SR, Kelsey KT, Berger MS, Wiencke JK.

Neuro Oncol. 2011 Mar;13(3):280-9. doi: 10.1093/neuonc/noq190.

21.

Diverse somatic mutation patterns and pathway alterations in human cancers.

Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S.

Nature. 2010 Aug 12;466(7308):869-73. doi: 10.1038/nature09208. Epub 2010 Jul 28.

PMID:
20668451
22.

Zinc finger nucleases as tools to understand and treat human diseases.

Davis D, Stokoe D.

BMC Med. 2010 Jul 1;8:42. doi: 10.1186/1741-7015-8-42. Review.

23.

Caring for people with end-stage dementia.

Birch D, Stokoe D.

Nurs Older People. 2010 Mar;22(2):31-6.

PMID:
20355343
24.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
25.

Converting cancer mutations into therapeutic opportunities.

O'Brien T, Stokoe D.

EMBO Mol Med. 2009 Sep;1(6-7):297-9. doi: 10.1002/emmm.200900044.

26.

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2010 Mar;97(1):33-40. doi: 10.1007/s11060-009-0004-4. Epub 2009 Aug 25.

27.

Oncogenic activating mutations are associated with local copy gain.

Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, Guerrero S, Lin WM, Pham T, Modrusan Z, Seshagiri S, Stern HM, Waring P, Garraway LA, Chant J, Stokoe D, Cavet G.

Mol Cancer Res. 2009 Aug;7(8):1244-52. doi: 10.1158/1541-7786.MCR-08-0532. Epub 2009 Aug 11.

28.

Genetic alterations and oncogenic pathways associated with breast cancer subtypes.

Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G.

Mol Cancer Res. 2009 Apr;7(4):511-22. doi: 10.1158/1541-7786.MCR-08-0107.

29.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

30.

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA.

J Clin Oncol. 2009 Feb 1;27(4):579-84. doi: 10.1200/JCO.2008.18.9639. Epub 2008 Dec 15.

31.

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F.

Cancer Res. 2008 Oct 1;68(19):8127-36. doi: 10.1158/0008-5472.CAN-08-0755.

32.

Signal transduction molecules in gliomas of all grades.

Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2009 Jan;91(1):19-26. doi: 10.1007/s11060-008-9683-5. Epub 2008 Sep 1.

33.

Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing.

Gräub R, Lancero H, Pedersen A, Chu M, Padmanabhan K, Xu XQ, Spitz P, Chalkley R, Burlingame AL, Stokoe D, Bernstein HS.

Cell Cycle. 2008 Jun 15;7(12):1795-803. Epub 2008 Jun 25.

34.

Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells.

Tamgüney T, Zhang C, Fiedler D, Shokat K, Stokoe D.

Exp Cell Res. 2008 Jul 1;314(11-12):2299-312. doi: 10.1016/j.yexcr.2008.04.006. Epub 2008 Apr 23.

35.

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D.

Biochem J. 2008 Oct 1;415(1):97-110. doi: 10.1042/BJ20080639.

36.

PTEN in brain tumors.

Haas-Kogan D, Stokoe D.

Expert Rev Neurother. 2008 Apr;8(4):599-610. doi: 10.1586/14737175.8.4.599. Review.

PMID:
18416662
37.

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.

Chen JS, Zhou LJ, Entin-Meer M, Yang X, Donker M, Knight ZA, Weiss W, Shokat KM, Haas-Kogan D, Stokoe D.

Mol Cancer Ther. 2008 Apr;7(4):841-50. doi: 10.1158/1535-7163.MCT-07-0393.

38.

New insights into PTEN.

Tamguney T, Stokoe D.

J Cell Sci. 2007 Dec 1;120(Pt 23):4071-9. Review.

39.

Tuberous sclerosis complex proteins 1 and 2 control serum-dependent translation in a TOP-dependent and -independent manner.

Bilanges B, Argonza-Barrett R, Kolesnichenko M, Skinner C, Nair M, Chen M, Stokoe D.

Mol Cell Biol. 2007 Aug;27(16):5746-64. Epub 2007 Jun 11.

40.

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.

Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D.

Neuro Oncol. 2007 Jul;9(3):271-9. Epub 2007 May 15.

41.

Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies.

Bilanges B, Stokoe D.

Oncogene. 2007 Sep 6;26(41):5973-90. Epub 2007 Apr 2. Review.

PMID:
17404576
42.

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO.

Nat Med. 2007 Jan;13(1):84-8. Epub 2006 Dec 10.

PMID:
17159987
43.

Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions.

Fujii N, Haresco JJ, Novak KA, Gage RM, Pedemonte N, Stokoe D, Kuntz ID, Guy RK.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):549-52. Epub 2006 Oct 6.

PMID:
17055267
44.

mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Panner A, Nakamura JL, Parsa AT, Rodriguez-Viciana P, Berger MS, Stokoe D, Pieper RO.

Mol Cell Biol. 2006 Oct;26(20):7345-57. Epub 2006 Aug 7.

45.

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA.

Cancer Cell. 2006 May;9(5):341-9.

46.

Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes.

Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA.

Mol Cancer Res. 2006 May;4(5):319-30.

47.

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM.

Cell. 2006 May 19;125(4):733-47. Epub 2006 Apr 27.

48.

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

Oda K, Stokoe D, Taketani Y, McCormick F.

Cancer Res. 2005 Dec 1;65(23):10669-73.

49.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

50.

Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.

Gottschalk AR, Doan A, Nakamura JL, Stokoe D, Haas-Kogan DA.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1221-7.

PMID:
16253776

Supplemental Content

Loading ...
Support Center